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A B S T R A C T  
Background: Streptococcal tonsillitis is a common pediatric ailment which is faced by physicians on a daily basis and is 
associated with disastrous complications if not treated adequately. The objective of this study was to compare the 
efficacy, safety and cost-effectiveness of intravenous co-amoxiclav with benzyl penicillin in the treatment of severe 
streptococcal tonsillitis in children. 
Material and Methods: This Randomized Controlled Trial was carried out at CMH Mardan, Khyber Pakhtunkhwa from 
January 2018 to November 2019. A total of 310 children with severe tonsillitis, aged between 5 to 15 years were 
selected from outpatient department of Combined Military Hospital Mardan. The cases were divided into two groups. 
Injection co-amoxiclav was given to patients in Group A (n=155) and injection benzyl penicillin was administered to 
patients in Group B (n=155). Both groups were compared in terms of effectiveness of treatment, safety and cost. All 
the data was assessed with help of SPSS (Statistical Package for Social Sciences) version 21. Chi square and 
independent t-test were used with P-value < 0.05 taken as statistically significant. 
Results: There were 310 children with severe tonsillitis, 155 in each group. Mean age in Group A was 9.35±3.17 years 
and in Group B, 9.96±2.96 years, respectively. In Group A, 2 cases developed hypersensitivity to injection co-amoxiclav 
after initial test dose as compared to 3 cases in Group B. Mean duration for complete resolution of symptoms (i.e. 
hospital stay) was 4.13±0.375 days for Group A as compared to 4.09±0.377 days for Group B (P=0.458). Mean cost of 
antibiotic drugs for each child in Group A was Rs. 965.88 ± 298 and in Group B was Rs. 152.36±53. Benzyl penicillin 
was found to be more cost effective as compared to co-amoxiclav (P=0.000). 
Conclusions: Both the drugs have similar efficacy and safety profile in the treatment of severe streptococcal tonsillitis 
in children. However, benzyl penicillin is more cost effective than co-amoxiclav in our study population. 
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I n t r o d u c t i o n  
 
Tonsillitis is defined as inflammation of pharyngeal 
tonsils, although infection may spread to lingual 
tonsils, adenoids and adjacent tissues.
1,2 
It is mostly 
caused by viral or bacterial infections. Group A 
Streptococcal tonsillitis is also called ‘Strept 
Throat’.3 Symptoms of tonsillitis include fever, pain 
throat, dysphagia, odynophagia, headache, chills, 
malaise, white pus-filled spots or membrane over 
tonsils and neck node enlargement.
4 
Pain of 
tonsillitis can also radiate to ears. The patient may 
also complain of fatigue, halitosis, anorexia, voice 
change etc.
3 
Most common cause of tonsillitis is 
viral, caused by adenovirus, rhinovirus, influenza, 
respiratory syncytial and coronavirus etc.
5 
Second 
common cause is bacterial tonsillitis. Among 
bacterial microorganisms, Group A β-hemolytic 
streptococcus (GAS), Streptococcus pyogenes is 
most frequently involved.
6,7 
Staphylococcus aureus 
(including Methicillin-Resistant Staphylococcus 
aureus), Streptococcus pneumoniae, Mycoplasma 
pneumoniae, Chlamydia Pneumoniae, etc. can also 
be responsible infrequently.
8
 Clinically, 
streptococcal pharyngitis/tonsillitis is diagnosed 
with the help of characteristic clinical features 
along with throat swab culture, which is the gold 
standard diagnostic test.  
In literature, streptococcal tonsillitis, pharyngitis 
and pharyngotonsillitis have been used 
synonymously/interchangeably.
9,10 
Prevalence of 
acute streptococcal pharyngitis /pharyngotonsillitis 
caused by GAS (Streptococcus pyogenes) varies 
from 20 to 30% and is the commonest cause of 
bacterial tonsillitis requiring antibiotics.
11,12
 The 
prevalence of acute streptococcal pharyngitis in 
Pakistan has been reported as 25.3%.
13
  
Streptococcal tonsillitis (tonsillitis or 
pharyngotonsillitis caused by GAS) requires 
treatment with antibiotics as it is associated with 
not only local suppurative complications like 
peritonsillar abscess, otitis media, mastoiditis and 
pneumonia but can also cause non-suppurative 
complications like acute rheumatic fever, acute 
post-streptococcal glomerulonephritis, post-
streptococcal reactive arthritis and pediatric 
autoimmune neuropsychiatric disorders. Penicillins, 
macrolides, cephalosporins, and clindamycin are 
highly sensitive against the Streptococci.
11,12 
Streptococcal tonsillitis can be confirmed in less 
than 10 minutes with 95% specificity and 80-90% 
sensitivity.
13 
In our resource-constrained country, 
economic factors are very important with regards 
to the treatment of streptococcal tonsillitis. 
In the present study, we have compared co-
amoxiclav with benzyl penicillin for the treatment 
of children with acute streptococcal 
tonsillitis/pharyngotonsillitis in terms of efficacy, 
safety and cost-effectiveness. 
M a t e r i a l  a n d  M e t h o d s  
This randomized single-blinded clinical trial was 
carried out at Combined Military Hospital Mardan, 
Khyber Pakhtunkhwa Pakistan from January 2018 
to November 2019. Permission was sought from 
the Ethical Review Board of the hospital and 
informed consent was obtained from the 
parents/guardian at the start of the study. Sample 
size was calculated with help of Epitools online 
sample size calculator. Prevalence of streptococcal 
pharyngitis was taken as 25.3%,
13
 with a confidence 
interval of 95%, sample of 291 was calculated.  
Children aged between 5 to 15 years, with a Centor 
Score for Strep tonsillitis /pharyngotonsillitis of 3 or 
4 and those who had a positive Rapid Antigen 
detection Test (RADT) for Group A beta-hemolytic 
streptococci were included in the study. 
Immunocompromised children, those with known 
allergy to penicillins (co-amoxiclav and benzyl 
penicillin), those on oral or parenteral antibiotics 
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and with liver failure or renal impairment were 
excluded from the study. 
The cases were selected from outpatient 
department of Combined Military Hospital Mardan, 
KPK. A child was diagnosed as a case of 
Streptococcal Tonsillitis/pharyngotonsillitis on the 
basis of Centor criteria,
14 
which includes the 
following: Fever >38.5ᵒC, anterior cervical 
lymphadenopathy, absence of cough and tonsillar 
exudate. Children with a Centor score of 4 or 3 
were grouped as “severe tonsillitis”, those with a 
Centor score of 2 were termed “moderate 
tonsillitis” and those with a Centor score of 1 were 
called “mild Tonsillitis”. The children were termed 
“healthy” when Centor score was 0. 
A total of 310 children fulfilling the inclusion criteria 
were admitted indoor. The cases were divided 
randomly through random number tables into two 
groups, Group A and Group B. Children in Group A 
(n=155) were given injection co-amoxiclav 50 
units/kg/day in 3 divided doses and those in Group 
B (n=155) were given injection benzyl penicillin 
25000 units/kg/day in 3 divided doses, 
intravenously.  
Both these groups were compared in terms of 
efficacy of treatment, safety and cost effectiveness. 
Efficacy was assessed through improvement/ 
decrease (reduction in fever, decrease in tonsillar 
exudates and settling lymphadenopathy) in Centor 
Criteria score on a daily basis. Improvement/ 
decrease in Centor Criteria score was charted for all 
cases till they recovered. Children were discharged 
after they had recovered fully and their Centor 
score became zero/nil. Group A children were 
prescribed syrup co-amoxiclav (50mg/kg/day 
divided in 3 doses) and Group B, syrup penicillin V 
(25 mg/kg/day in 3 divided dosage) to complete the 
ten days antibiotics course.  
Safety was assessed by recording the frequency of 
hypersensitivity reactions and serious side effects 
of antibiotics leading to the withdrawal of the 
offending injection/drug. Children in both groups 
were administered a test dose of the antibiotic 
before injecting full dose of benzyl penicillin or co-
amoxiclav. The procedure of test dose comprised of 
giving 10% of antibiotic dose slowly intravenously 
over 5 minutes. The child was subsequently 
observed for any allergic reaction (urticaria, 
shortness of breath, angioedema, itching, nausea, 
vomiting, anaphylaxis, etc.) for 30 to 60 minutes. A 
trained nurse supervised the test dose and full dose 
administration. All the cases were also observed for 
any serious side effects of both antibiotics. In 
Group A (co-amoxiclav group), children were 
observed for severe vomiting, diarrhea, abdominal 
pain and clinical jaundice. In Group B (benzyl 
penicillin group), children were observed for 
seizures and blood dyscrasias. Complete blood 
picture, liver and renal function tests were carried 
out every 48 hours to detect any serious side effect 
of the antibiotics being used. 
Cost effectiveness was compared in terms of total 
cost of injections (co-amoxiclav versus benzyl 
penicillin), which were administered to the children 
of both groups.  
Data was analyzed with help of SPSS (Statistical 
Package for Social Sciences) version 21.  
Frequencies were expressed by percentages. Chi 
square test was used to compare the qualitative 
variables, while independent T test was used to 
analyze quantitative variables. P-value < 0.05 was 
taken as statistically significant.  
Clinical Trial Registration: Clinicaltrials.gov-
NCT04215770. 
R e s u l t s  
There were 310 cases, 155 in each group. Overall, 
there were 163 (52.58%) males and 147 (47.42%) 
females. The age range of patients was from 5 to 15 
years with a mean age of 9.66 ± 3.08 years. Both 
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groups A and B were matched in terms of age and 
gender (Table I). 
Table I: Baseline characteristics of group A and B 
(n=310) 
Variables Group A Group B P-value* 
Mean Age 
(Years) 
9.35±3.17 9.96±2.96 0.083 
Male 
(n=163) 
80 (51.61%) 83 (53.55%) 
0.733 
Female 
(n=147) 
75 (48.39%) 72 (46.45%) 
*P-value <0.05 was considered statistically significant 
Group A-Injection coamoxiclav; Group B-Injection benzyl 
penicillin 
 
Centor score was evaluated and documented for 
each child on admission, then checked daily and 
recorded till the child recovered i.e. Centor score 
was nil/zero. Children were discharged from 
hospital when Centor score became nil/zero. Table 
II shows mean Centor score record of children on 
admission and subsequent days till recovery. Mean 
duration for complete resolution i.e. hospital stay 
was 4.13+0.375 days in Group A, and 4.09+0.377 
days in Group B (P=0.458). 
The overall frequency of allergic reactions to both 
penicillin group antibiotics was 1.61%. There were 
only 2 (1.29%) cases of allergic reactions in Group A 
and 3 (1.94%) cases in Group B, indicating that both 
antibiotics are safe for use in children (P=0.652). 
There were no serious side effects to any of these 
two antibiotics in our study, except the allergic 
(hypersensitivity) reactions. Regular complete 
blood picture, liver and renal function tests in all 
cases were normal and did not show any blood 
dyscrasias, liver or renal compromise. Mean cost of 
antibiotic drug for each child in Group A was Rs. 
965.9 ± 298 and in Group B, Rs. 152.4 ± 52.8. There 
was significant difference in cost of both these 
injections, benzyl penicillin being more cost 
effective (P=0.000). Price of one intravenous 
injection of amoxiclav 600mg was Rs. 80
15
 and that 
of benzyl penicillin 5 lac units was Rs. 8,
16
 
respectively (Table III). 
Table II: Comparison of both Groups in terms of daily 
Centor Score 
Day Centor 
Score 
Recorded 
Groups n 
Mean 
Centor 
Score 
SD 
P-
value* 
Admission 
Day  
Group A 155 3.96 0.195 
0.768 
Group B 155 3.97 0.179 
Day 1  
Group A 155 2.97 0.396 
0.340 
Group B 155 2.93 0.447 
Day 2  
Group A 155 2.12 0.419 
0.054 
Group B 155 2.03 0.406 
Day 3  
Group A 155 1.11 0.390 
0.472 
Group B 155 1.08 0.391 
Day 4  
Group A 155 0.14 0.352 
0.632 
Group B 155 0.13 0.332 
Day 5  
Group A 155 0.01 0.081 
0.559 
Group B 155 0.01 0.114 
*P-value <0.05 was considered statistically significant.  
Group A-Children on Injection coamoxiclav; Group B-
Children on Injection benzyl penicillin; SD-Standard 
Deviation; n-Number of children 
D i s c u s s i o n  
Streptococcal tonsillitis/pharyngotonsillitis is one of 
the most common cause of hospital visits in 
children. It can cause serious complications 
including rheumatic heart disease and acute renal 
failure.
14
 Antibiotics have to be used to eradicate 
Streptococcus pyogenes to prevent these 
complications which are serious health issues and 
cause of a worldwide economic burden. 
Co-amoxiclav and benzyl penicillin both belong to 
the Penicillin group of antibiotics. They are beta-
lactam antibiotics with bactericidal action and are 
effective against Streptococcus pyogenes. In 
literature, the allergic reactions of penicillins occur 
1 in 5000 patients.
17 
In Pakistan, till date, no such study has been carried 
out to compare these two drugs for tonsillitis or 
pharyngotonsillitis.  
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Table III: Comparison of cost-effectiveness of group A and group B antibiotics 
Groups Antibiotics n 
Mean Cost 
(Rs.) 
Standard Deviation 
Total cost 
(Rs.) 
P-value* 
A Co-amoxiclav 155 965.88 297.99 147780.0 
0.000 
B Benzyl Penicillin 155 152.36 52.82 23160.0 
Total  310 560.46 460.19 170940.0  
*P-value <0.05 was considered statistically significant 
Baomah et al. compared co-amoxiclav with benzyl 
penicillin in the treatment of Ludwigs angina in 
Ghana, and found that both these drugs are equally 
effective.
18 
Agweyu et al. compared oral amoxycillin 
with benzyl penicillin in Kenyan children with 
severe pneumonia and found no difference in their 
efficacy.
19 
Atkinson et al. compared oral amoxicillin 
with intravenous benzyl penicillin in patients of 
community-acquired pneumonia, and found equal 
efficacy of these two pharmacologic agents.
20 
Similarly, we found both these drugs safe and 
equally effective in treating severe tonsillitis or 
pharyngotonsillitis in children. However, there was 
significant difference in cost-effectiveness of both 
these drugs: Benzyl penicillin being very cheap as 
compared to co-amoxiclav. As already mentioned, 
one Injection of co-amoxiclav 600mg costs Rs. 
80.00 versus Rs 08.00 of benzyl penicillin.
15,16 
Thus, 
there is significant difference of prices between the 
two drugs with similar efficacy and safety profile.
18
 
C o n c l u s i o n  
Intravenous co-amoxiclav and benzyl penicillin have 
similar efficacy and safety profile in the treatment 
of severe streptococcal tonsillitis. However, benzyl 
penicillin is more cost effective than co-amoxiclav 
in our study population. 
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